Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform ...

Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their ...

Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and develop multiple bispecific antibodies. The ...

Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the so-called “abortion pill ...

The National Institutes of Health's National Library of Medicine has released the pilot version of a new tool designed to ...

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...

ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public ...

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug ...

On Wednesday, the molecular and clinical genetics panel of the FDA’s medical devices advisory committee sat down and debated Grail’s hotly anticipated Galleri test. The tech works as a simple blood ...

Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases. | Roche has penned a backloaded $2 billion deal ...

As the U.S. government faces up to China's expanding role in the global biopharma ecosystem, one senator has been looking at the bigger picture. | Senator Todd Young (R-IN), chairman of the National ...

Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug that the Big Pharma bought in a $3 billion takeover.